Introduction: Hematologic malignancies, including leukemias, lymphomas, and myeloma, can involve the central nervous system (CNS) at the time of diagnosis or later in relapse. CNS involvement can lead ...

Frontiers in Cell and Developmental Biology… Cancer Cell Biology… Research Topics Frontiers in Cell and Developmental Biology ...

Our presence at this congress highlights our commitment to addressing global unmet medical needs in hematological malignancies and lung cancer," said Xiaolin Zhang ... good central nervous system (CNS ...

Findings from St. Jude Children's Research Hospital show FOXR2 activation in multiple pediatric CNS tumor types, mostly brain tumors, with significantly different clinical outcomes. The ...

Today, the overall survival for children with malignancies approaches 80% and is truly one of the success stories in modern day medicine (1). The progress in the treatment of pediatric malignancy ...

Expert Rev Hematol. 2012;5(3):325-340. The distinct pattern of expression in postembryonic tissues may be of importance for EPHA3 as a novel focus for targeted therapy, as with scant receptor ...

Jude Department of Pediatric Medicine. "The CNS neuroblastomas had an exceptionally good outcome when they were treated with multimodal therapy, whereas the other types of tumors in the cohort ...

Table 1. Common causes and pathogenic mechanisms of acute and chronic renal impairment in patients with hematological malignancies. Category Causes and pathogenetic mechanisms Ref. Disease ...

Our experts at Sibley Memorial and Suburban Hospital combine the science and research of Johns Hopkins with excellent patient care you have come to expect. The most innovative and advanced cancer care ...

Medulloblastoma (MB) is the most common pediatric CNS malignancy comprising ... exposure Ovarian cancer (OC) survivors may develop therapy-related myeloid neoplasia (TMN), and the risk is higher after ...

Complete the form below to unlock access to ALL audio articles. Those differences indicate that physicians should not use FOXR2 activation as an exclusive marker of CNS neuroblastoma since it can ...